Skip to main content
Clinical Trials/NCT01551901
NCT01551901UnknownNot Applicable

LIFT: Luna Interbody System for Fusion Trial

Benvenue Medical, Inc.9 sites in 2 countries100 target enrollmentStarted: January 2012Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
100
Locations
9
Primary Endpoint
Maintenance or improvement of neurologic function related to the spine

Study Overview

Brief Summary

The purpose of this trial is to evaluate the performance, safety and effectiveness of the Luna system for the treatment of degenerative disc disease.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age 18 - 65 at the time of consent
  • Patient has back pain consistent with symptomatic degenerative disc disease at one level or two contiguous levels from L2-S1 requiring surgical intervention.
  • Patient has had at least 6 months of non-operative care
  • Patient is mentally capable and willing to sign a study-specific informed consent form
  • Patient is willing and able to comply with all study requirements
  • Patient has a score on the back pain visual analog scale (VAS) of ≥ 40 mm
  • Patient has an Oswestry Disability Index (ODI) score of ≥ 30%

Exclusion Criteria

  • DDD affecting >2 levels
  • Back pain due to causes other than DDD
  • Spine surgery within last 3 months or planned spine surgery within 6 weeks of post study procedure
  • >Grade 1 spondylolisthesis or retrolisthesis
  • Infection at or close to target disc level
  • Active systemic infection
  • Patient has known osteoporosis
  • Prior interbody fusion at the target level
  • Prior failed interbody fusion at any level
  • Known allergy to device materials
  • Uncontrolled psychiatric illness or severe dementia
  • Pregnant at time of enrollment or considering getting pregnant during study period
  • Any metabolic or other bone disease that could significantly compromise pedicle screw and/or interbody device placement.
  • Any severe illness that would prevent complete study participation
  • Uncontrolled diabetes
  • Current use of chronic steroids (more than equivalent of 10 mg prednisone daily)
  • Contraindication to spinal surgery or general anesthesia
  • Coagulopathy
  • Body mass index >35
  • Current smoker
  • Known illicit substance abuser
  • Currently participating in another investigational study that could affect responses to the study device

Outcomes

Primary Outcomes

Maintenance or improvement of neurologic function related to the spine

Time Frame: 12 Month Post-op

Proportion of subjects with device in place showing lack of device migration or subsidence and absence of device related serious adverse event

Time Frame: 12 Month Post-op

Improvement in pain score on the Visual Analog Scale (VAS) from baseline

Time Frame: 12 Month Post-op

Proportion of subjects with lack of revision, removal, reoperation or use of additional supplemental fixation

Time Frame: 12 Month Post-op

Improvement in Oswestry Disability Index (ODI) score from baseline

Time Frame: 12 Month Post-op

Secondary Outcomes

  • Improvement from baseline in quality of life as measured by SF-36(12 Month Post-op)
  • Rate of device-related serious adverse events(12 Month Post-op)
  • Proportion of subjects with radiographic fusion of target segments(12 Month Post-op)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (9)

Loading locations...

Similar Trials